Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXR3V1)

Drug Name

DNP-004089 Drug Info

Synonyms

BACE inhibitors, De Novo; Beta-amyloid converting enzyme inhibitors,De Novo; Beta-secretase inhibitors, De Novo

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Terminated	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Beta-secretase (BACE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(S)-FLURBIPROFEN	DMF2O4T	Myalgia	FB56.2	Preregistration	[3]
E-2609	DMTNUJ8	Alzheimer disease	8A20	Phase 3	[4]
verubecestat	DM4CGH5	Alzheimer disease	8A20	Phase 3	[5]
Lanabecestat	DMFJLB6	Alzheimer disease	8A20	Phase 3	[6]
AZD3293	DMJQHXD	Alzheimer disease	8A20	Phase 2/3	[7]
JNJ-54861911	DMGPJ5U	Alzheimer disease	8A20	Phase 2/3	[6]
R-flurbiprofen	DMFIVSR	N. A.	N. A.	Phase 2	[3]
LY2886721	DMV14LM	Alzheimer disease	8A20	Phase 2	[8]
LY3202626	DM7IFNB	Alzheimer disease	8A20	Phase 2	[6]
AZD-3839	DM72FOD	Alzheimer disease	8A20	Phase 1	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020178)
2	US patent application no. 8,269,019, Inhibitors.
3	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
4	Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
5	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
8	Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
9	Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.